Clinical trials recruiting for Metastatic Triple-Negative Breast Carcinoma

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
  NCT07078604 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
  NCT06246968 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
  NCT05770531 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
  NCT06176261 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
  NCT04348747 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 3 locations
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
  NCT06492759 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
  NCT05318469 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neratinib in Combination With Ruxolitinib in Patients With mTNBC
  NCT06008275 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
  NCT06324240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
  NCT05741164 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
  NCT06774027 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
  NCT06434064 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
  NCT06505018 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 51 locations
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
  NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
  NCT07137416 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
  NCT05451784 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations

Related conditions

Trials recruiting for Metastatic Triple-Negative Breast Carcinoma often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Metastatic Triple-Negative Breast Carcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.